|
(Health-NewsWire.Net, September 23, 2021 )
Market Overview
Biobetters are improved versions of originator biologics which are similar to existing biologics entities by action, potency and by other factors. Biobetters are formed as a result of chemical modification, protein fusion, altered amino acid sequence, or humanization of the glycosylation pattern, which aims for the same target as the original biological, but has its effect longer period of time, typically at lower doses and with fewer side effects. Biobetters are therapeutically more efficient medicines as compared to their respective originator biologic drugs.
View full report: https://bit.ly/3ADZTjN
Market Dynamics
The global biobetters market growth is driven by the increasing usage of therapeutically more effective drugs for the treatment of chronic diseases is expected to drive the growth of biobetters market. Higher efficacy and lower adverse effects are among the important factors that are expected to fuel the growth of the biobetters market over the forecast period.
The advantages of biobetters such as superior therapeutic efficacy, lower adverse effects, is driving the growth of the market
The developments in biotechnology, advances are being made in the treatment of most of the diseases. One such most important advent is biobetters. The major drivers of the biobetters market are the advantages of biobetters such as superior therapeutic efficacy, lower adverse effects, easier and less costly manufacturing processes, non-patent and market exclusivity, longer product half-life, less dosing frequency and availability of high investment opportunities in this sector.
A biobetter can be assigned a premium price for its improved characteristics, compared to other similar biologics. However, due to reduction in the number of dosages required, significant cost savings can be achieved. Hence, this impacts the willingness of payers to purchase the product. One such example is Neulasta- a Biobetter of Amgen Inc, to its own drug Neupogen. A single treatment cycle of Neupogen costs USD 6000, whereas Neulasta is USD 3400, though the per unit price of Neupogen is USD 300 and Neulasta is USD 3400. Hence, there is a 40% reduction in the overall cost to the healthcare provider. Thus, the biobetters market is estimated to grow rapidly during the forecast period.
Growing investment in developing therapeutic agents of higher efficacy is anticipated to stimulate the market growth.
The pressing need for finding out a way to improve the safety and efficacy of biologics has made biobetters as a tough contender against biosimilars. Growing investment in developing therapeutic agents of higher efficacy and safety profiles for cancers and autoimmune diseases has shaped the growth dynamics of the biobetters market. Over the past few years, there have been concerted efforts in reducing the economic burden of these diseases. Expanding array of monoclonal antibodies has also made a positive bearing on the biobetters market. Growing incidence of chronic diseases such as chronic kidney disease and chemotherapy-induced anemia has also added to the expansion of the market. The development of biobetters is also followed as a defense strategy by the originator companies, to protect their market niche against biosimilars and also to overcome patent issues. For instance, the subcutaneous formulation of Roche’s trastuzumab was released into the market in 2013, before Roche’s Herceptin (intravenous trastuzumab) patent expired in 2014. These factors are driving the growth of the market in the forecast period.
Increasing biosimilar competition is likely to hinder the market growth
On the contrary, high investment in research and development and the increasing biosimilar competition is restraning the market growth in the forecast period.
Segment Analysis
By Drug Class
• Erythropoietin Biobetters
• Insulin Biobetters
• G-CSF Bioreactors
By Application
• Cancer
• Diabetes
• Renal Disease
By Route of Administration
• Oral
• Subcutaneous
• Inhaled
By Distribution Channel
• Hospital Pharmacy
• Pharmacy Stores
• Other
Download free sample: https://bit.ly/3EJna6p
Geographical Analysis
North America region holds the largest market share global Biobetters market
North America region is dominating the global biobetters market accounted for the largest market share in 2020. The United States is the global leader in the biobetters market. According to the Pharmaceutical Research and Manufacturers Association, over half of the world’s R&D in pharmaceuticals (USD 75 billion) and the Intellectual Property Rights of most new medicines are held by the United States. Also, most of the biobetters in the US are getting into collaborations and partnerships with the regional players and investing funds in research and development. For instance, Kadcyla drug developed by Roche, approved in 2019 is an adjuvant treatment for HER2- positive early breast cancer in patients affected by residual invasive disease post neoadjuvant taxane-trastuzumab-based treatment.
Asia-pacific has the highest growth rate due to various large and medium-sized pharmaceutical and biopharmaceutical companies are looking to develop biobetters as the process of manufacturing is comparatively easier. Partnerships with various global players is enabling the regional market players to enhance their product offering as well as technology transfer in return for their higher regional reach.
Competitive Landscape
The Biobetters market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Amgen Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi SA, SERVIER, Porton Biopharma Limited, Eli Lily and Company, Novo Nordisk A/S, Biogen Inc., CSL Behring GmbH, and Teva Pharmaceutical Industries Ltd., among others.. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Biobetters market globally.
Related Topic's
Biodefense Market, Biomaterial Wound Dressing Market, Biomarkers Market, Biosurgery Market, Biotech Ingredients Market
DataM Intelligence
Sai Kiran
+1 877 441 4866
pr@datamintelligence.com
Source: EmailWire.Com 
|
